MedTrace Logo

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2026-02-10

No results posted yet for this study

Summary

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option.

ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

Conditions

  • Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
  • Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Interventions

DRUG

ARV-393

Oral daily dose of ARV-393 at a specified dose level

DRUG

Glofitamab

Glofitamab infusion per labelled prescribing information

Sponsors & Collaborators

  • Arvinas Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-05
Primary Completion
2028-03-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Denmark
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06393738 on ClinicalTrials.gov